By admin 
CureSearch for Children’s Cancer, a leading global nonprofit dedicated to ending childhood cancer by driving targeted and innovative research, has officially named Dr. Robbie Majzner of the Dana-Farber Cancer Institute as the recipient of the 2026 CureSearch Catapult Award. This significant $2 million investment, co-funded in partnership with the Jeff Gordon Children’s Foundation, is earmarked to launch a Phase I clinical trial for a next-generation Chimeric Antigen Receptor (CAR) T-cell therapy. The treatment is specifically designed for children and young adults battling relapsed or refractory neuroblastoma, a patient population that currently faces a critical lack of effective therapeutic options and a grim long-term prognosis.
The Catapult Award serves a unique and essential role in the oncology ecosystem. It is specifically structured to bridge the "translational gap"—often referred to in the scientific community as the "Valley of Death"—where promising laboratory discoveries frequently stall due to a lack of funding for the expensive and complex transition into human clinical trials. By providing substantial financial backing at this juncture, CureSearch aims to accelerate the delivery of high-potential treatments from the bench to the bedside, offering hope to families for whom standard-of-care treatments have failed.
The Burden of Neuroblastoma in Pediatric Oncology
Neuroblastoma is a cancer that develops from immature nerve cells found in several areas of the body, most commonly arising in and around the adrenal glands. It stands as the most common extracranial solid tumor in children, accounting for approximately 7% to 10% of all pediatric cancer cases and more than 10% of all childhood cancer-related deaths.
For clinicians and researchers, the "high-risk" subset of neuroblastoma patients presents the greatest challenge. Despite an aggressive multi-modal treatment regimen that typically includes high-dose chemotherapy, surgical resection, radiation therapy, stem cell transplants, and monoclonal antibody treatments, the five-year survival rate for high-risk patients remains stubbornly below 50%. For those who experience a relapse or whose cancer is refractory (unresponsive) to initial treatments, the survival statistics are even more concerning. Furthermore, the intensity of current treatments often results in long-term "late effects" for survivors, including hearing loss, growth impairment, cardiac issues, and secondary malignancies, highlighting the urgent need for more targeted, less toxic interventions.
The Evolution and Limitations of Immunotherapy
The emergence of CAR T-cell therapy has been one of the most significant breakthroughs in modern oncology. This approach involves extracting a patient’s own T-cells—the "soldiers" of the immune system—and genetically engineering them in a laboratory to express specific receptors on their surface. These receptors allow the T-cells to recognize and bind to specific proteins, or antigens, found on the surface of cancer cells. Once infused back into the patient, these "living drugs" seek out and destroy the malignancy.
While CAR T-cell therapy has achieved remarkable success and multiple FDA approvals for hematologic malignancies, such as B-cell acute lymphoblastic leukemia (ALL) and certain lymphomas, its application in solid tumors has been fraught with difficulties. Solid tumors like neuroblastoma present a hostile microenvironment that can suppress immune activity. A primary obstacle is "T-cell exhaustion," a state where the engineered cells become overstimulated and lose their ability to replicate or kill cancer cells effectively. In previous trials targeting neuroblastoma, CAR T-cells often failed to persist long enough in the patient’s body to achieve a complete and lasting remission.
The ZAP70 Innovation: A New Architecture for Persistence
Dr. Robbie Majzner and his research team at Dana-Farber Cancer Institute have developed a novel solution to the problem of immune exhaustion. Their approach continues to target GD2, a disialoganglioside that is highly expressed on the surface of almost all neuroblastoma cells. However, the innovation lies in the internal signaling mechanism of the CAR itself.
The team has incorporated a signaling protein known as ZAP70 (Zeta-chain-associated protein kinase 70) into the CAR architecture. In natural immune responses, ZAP70 plays a critical role in T-cell activation. By integrating this protein into the engineered CAR T-cells, Dr. Majzner aims to mimic a more natural and sustainable activation signal. Preclinical data published by the team indicates that these redesigned cells demonstrate significantly enhanced anti-tumor activity and, crucially, a much higher degree of persistence. Unlike traditional GD2 CAR T-cells that may burn out quickly, the ZAP70-augmented cells appear to remain active and vigilant for longer periods, providing a sustained attack against the tumor.
Initial laboratory models have also suggested a potentially improved safety profile. While GD2 is a potent target for neuroblastoma, it is also expressed at low levels on some healthy nerve tissues, which can lead to side effects like severe pain during treatment. The new architecture aims to optimize the "therapeutic window," maximizing the destruction of cancer cells while minimizing impact on healthy tissue.
Strategic Funding and Chronology of the Catapult Award
The 2026 CureSearch Catapult Award represents a culmination of years of rigorous scientific review and strategic planning. CureSearch utilizes a stringent selection process, involving an International Advisory Board of experts who evaluate proposals based on their potential for clinical impact and the likelihood of reaching the market as an approved therapy.
The timeline for this initiative is structured to move rapidly:
- Discovery Phase: Dr. Majzner’s team spent several years identifying the limitations of existing GD2 therapies and engineering the ZAP70 signaling protein.
- Preclinical Validation: Successful testing in laboratory and animal models demonstrated the superiority of the new CAR architecture over previous iterations.
- The Catapult Award (2026): The $2 million grant provides the necessary capital to manufacture the clinical-grade cells and initiate the Phase I trial.
- Phase I Clinical Trial: The upcoming trial will enroll children and young adults with relapsed or refractory neuroblastoma to evaluate the safety, tolerability, and optimal dosing of the therapy.
The partnership with the Jeff Gordon Children’s Foundation is a cornerstone of this funding. Founded by the four-time NASCAR Cup Series champion, the foundation has a long-standing history of supporting pediatric cancer research. This collaboration underscores a growing trend in the nonprofit sector where organizations pool resources to fund high-stakes, high-reward research that might be considered too risky for traditional government or pharmaceutical funding at an early stage.
Official Responses and Clinical Perspectives
The announcement has been met with optimism from the pediatric oncology community. Dr. Robbie Majzner emphasized the transformative nature of the funding, stating that current GD2 CAR T-cells have historically only been effective in patients with a very low disease burden. "We’ve designed a brand-new CAR architecture that breaks past limitations to success in lab models," Majzner noted. He further explained that the Catapult Award provides the "momentum" necessary to move the science out of the laboratory and into the clinical setting where it can directly affect patient outcomes.
Representing the funding organization, Dr. Paisley Myers, Senior Director of Research & Programs at CureSearch, highlighted the strategic intent behind the award. "One of the greatest challenges in pediatric cancer research is ensuring that promising discoveries reach children," Myers said. She characterized Dr. Majzner’s work as "bold, high-potential research" that aligns perfectly with the mission of the Catapult program.
Broader Implications for the Field of Oncology
The implications of this Phase I trial extend beyond the treatment of neuroblastoma. If the ZAP70 signaling architecture proves successful in humans, it could provide a blueprint for treating other solid tumors that have traditionally been resistant to CAR T-cell therapy. GD2 is not unique to neuroblastoma; it is also expressed in other pediatric and adult malignancies, including osteosarcoma, melanoma, and certain types of brain tumors (such as H3K27M-mutant diffuse intrinsic pontine glioma).
Furthermore, this trial represents a shift toward more sophisticated genetic engineering in immunotherapy. By moving beyond simple "on/off" switches and toward "tunable" signaling pathways like ZAP70, researchers are gaining finer control over the immune system’s response to cancer. This level of precision is essential for the next generation of cancer treatments, which aim to be both more effective and less debilitating for the patient.
As the Phase I trial progresses at Dana-Farber, the data collected will be vital for the global oncology community. It will provide insights into T-cell kinetics, cytokine responses, and the ability of engineered cells to penetrate solid tumor masses in humans. For the families of children with high-risk neuroblastoma, the launch of this trial represents a significant step toward a future where a relapse is no longer a terminal diagnosis, but a challenge that can be met with advanced, durable, and life-saving science.
